eGFR Decline in Patients with IgAN Treated with Nefecon or Placebo: Results from the 2-year NEFIGARD Phase 3 Trial

Conclusion: These results strongly indicate that Nefecon preserved kidney function and provide support for Nefecon as a disease-modifying therapy in patients with IgAN.

Methods
- 18 years
- Primary IgAN
- eGFR 30-90 ml/min/1.73m²
- UPCR ≥0.8 g/g or PrU ≥ 1 g/24h w/RAASi

Endpoints: Time to reach ↓30% in eGFR or kidney failure

Intervention
- Screening
- Treatment double-blinded
  - Nefecon 16 mg/day
  - Placebo
- Follow-up double-blinded
  - 15 months of observation off the drug

Results
- Change in eGFR 9 months
  - Nefecon: +%1.2%
  - Placebo: +%8.2%
- Change in eGFR 24 months
  - Nefecon: %−11%
  - Placebo: %−21.5%

Outcomes
- Risk of ↓30% in eGFR irrespective of UPCR category (< or > 1.5 g/g)
- Time to ↓30% in eGFR slower in Nefecon group HR 0.45; p=0.0014
- ↓41% in time-averaged UPCR in Nefecon group p<0.0001
- Tx effect ≈ despite rescue medication.

Endpoints: Time to reach ↓30% in eGFR or kidney failure

Lafayette R, et al
VA by @GabyNeph

WCN '24